Search

Displaying results 1661 - 1670 of 8696 in total
  1. Target

    Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1

    go.drugbank.com/bio_entities/BE0018277
    TargetHumans

    Functional component of the Nogo receptor signaling complex (RTN4R/NGFR) in RhoA activation responsible for some inhibition of axonal regeneration by myelin-associated factors (PubMed:14966521, PubMed:

    Polypeptides: Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1Synonyms: Leucine-rich repeat neuronal protein 1, Leucine-rich repeat neuronal protein 6A
  2. Drug

    Remestemcel-L

    go.drugbank.com/drugs/DB13973
    ApprovedInvestigationalWithdrawn

    It was approved for use in Canada in May 2012 as Prochymal for the management of refractory acute Graft versus Host Disease (aGvHD) in children who are unresponsive to systemic steroid therapies, with … Remestemcel-L is a third-party, off-the-shelf suspension of ex-vivo cultured adult human mesenchymal stem cells intended for intravenous infusion.

  3. Drug

    Trimethoprim

    go.drugbank.com/drugs/DB00440
    ApprovedInvestigationalVet approved

    [L11893] Trimethoprim is often used in combination with [sulfamethoxazole] due to their complementary and synergistic mechanisms but may be used as a monotherapy in the treatment and/or prophylaxis of … Trimethoprim is an antifolate antibacterial agent that inhibits bacterial dihydrofolate reductase (DHFR), a critical enzyme that catalyzes the formation of tetrahydrofolic acid (THF) - in doing so, it

    Mixtures: MAXTRIM-P, Hampiseptol Solution For InjectionCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  4. Drug

    Lasmiditan

    go.drugbank.com/drugs/DB11732
    ApprovedInvestigational

    Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019. … Their use is not devoid of concerns, however, and their vasoconstrictive activity can lead to blood pressure lability and other cardiovascular side effects - for this reason, these medications are less

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  5. Drug

    Dasiglucagon

    go.drugbank.com/drugs/DB15226
    Approved

    [L39190] Severe hypoglycemia is an acute, life-threatening medical condition resulting from a profound drop in blood glucose levels. … [L39200] Treatments for severe hypoglycemia have mostly been limited to intravenous dextrose and different glucagon formulations.

    Categories: Glucagon Receptor Agonists
  6. Drug

    Activated charcoal

    go.drugbank.com/drugs/DB09278
    ApprovedInvestigational

    It is activated by an oxidizing gas flow at high temperature passed over its surface to make a fine network of pores, producing a material with large surface area and high affinity for various substances … It works by binding to the poison in the gastric contents in a reversible fashion thus may be adminstered together with a cathartic to reduce the small intestine transit time.

    Products: Norit Carbomix 50 g Granulat zur Herstellung einer Suspension zum Einnehmen
  7. Drug

    Levoketoconazole

    go.drugbank.com/drugs/DB05667
    Approved

    It possesses most of the inhibitory effect towards steroidogenic enzymes, making it an attractive candidate for CS treatment with a potentially lower toxicity profile than its racemate.

    Categories: Corticosteroids for Systemic Use, P-glycoprotein inhibitors
  8. Drug

    Fluorouracil

    go.drugbank.com/drugs/DB00544
    ApprovedInvestigational

    A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

    Mixtures: Verrumal - Lösung zur äußerlichen Anwendung, Actikerall 5 mg/g + 100 mg/g Lösung zur Anwendung auf der HautCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  9. Drug

    Netarsudil

    go.drugbank.com/drugs/DB13931
    ApprovedInvestigational

    inhibitor to the rho kinase and norepinephrine transporters found there as opposed to affecting protaglandin F2-alpha analog like mechanisms in the unconventional uveoscleral pathway that many other glaucoma … with norepinephrine transport inhibitory activity that reduces production of aqueous As of December 18, 2017 the FDA approved Aerie Pharmaceutical's Rhopressa (netarsudil ophthalmic solution) 0.02% for

  10. Drug

    Ziprasidone

    go.drugbank.com/drugs/DB00246
    ApprovedInvestigational

    [A190525] Luckily, several treatment options for psychotic disorders have been introduced to market since the realization of chlorpromazine's antipsychotic properties in 1952. … [A190525] These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsProducts: Zeldox 20 mg/ml - Pulver zur Herstellung einer Injektionslösung